IPP Bureau
EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers
By IPP Bureau - March 17, 2026
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors
By IPP Bureau - March 17, 2026
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
By IPP Bureau - March 17, 2026
The company announced positive topline data from the Phase 3 ADorable-1 trial
Merck doubles down on cardio-pulmonary breakthroughs
By IPP Bureau - March 17, 2026
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea
By IPP Bureau - March 17, 2026
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
By IPP Bureau - March 17, 2026
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Cupid unveils “Made in India, Japanese Quality” branding to boost global presence
By IPP Bureau - March 17, 2026
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
L&T Tech unveils AI-powered lung digital twin platform
By IPP Bureau - March 17, 2026
LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs
Johnson & Johnson reports promising early results for targeted bladder cancer therapy
By IPP Bureau - March 17, 2026
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
By IPP Bureau - March 16, 2026
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer
By IPP Bureau - March 16, 2026
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
By IPP Bureau - March 16, 2026
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
By IPP Bureau - March 16, 2026
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
First patient dosed in trial of novel drug targeting limb-threatening artery disease
By IPP Bureau - March 16, 2026
The trial will enroll up to 42 patients in Finland across four cohorts
